Gladwin, Mark, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Gladwin, Mark, MD sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Gladwin, Mark, MD: 11 sponsored US clinical trials, none currently recruiting.

Gladwin, Mark, MD sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sedentary Lifestyle, with 1 trials.

Top-decile sponsor footprint

Gladwin, Mark, MD ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

7 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 2

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age

NCT04405180
TERMINATED Phase 2

Oral CXA-10 in Pulmonary Arterial Hypertension

NCT04125745
TERMINATED Phase 2

Transfusion of Biotin-Labeled Red Blood Cells

NCT03364686
COMPLETED Phase 1

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
COMPLETED Phase 2

Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction

NCT02918552
COMPLETED Phase 2

Oral Nitrite for Older Heart Failure Patients

NCT02457260
COMPLETED Phase 2

The Effects of NOx and Conjugated Linoleic Acid on Asthmatics

NCT02433977
COMPLETED Phase 2

Oral Nitrite in Adults With Metabolic Syndrome and Hypertension

NCT01681810
COMPLETED Phase 1

Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults

NCT01681836
TERMINATED Phase 1

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

NCT01848301
TERMINATED Phase 2

Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction

NCT01715883

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 8

Therapeutic Areas

Sedentary Lifestyle 1
Frailty 1
Asthma 1
Aging 1
Heart Failure 1

How the Gladwin, Mark, MD early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 7 completed (64%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Sedentary Lifestyle (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gladwin, Mark, MD: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gladwin, Mark, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Gladwin, Mark, MDAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Gladwin, Mark, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gladwin, Mark, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gladwin, Mark, MD page

11 registered trials is a research-attention snapshot, not an endorsement of Gladwin, Mark, MD or any single study.

  • None of Gladwin, Mark, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Sedentary Lifestyle is the condition Gladwin, Mark, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sedentary Lifestyle trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gladwin, Mark, MD pipeline card: 11 registered trials from official public datasets.Report a data error.